Clostridium Difficile Diagnostics and Treatment Market - by Product Type (By Drug (Metronidazole, Vancomycin, Fidaxomicin, and Bezlotoxumab), By Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), and Others)), By Distribution Channel (Hospitals & Clinics, Diagnostic Laboratories, and Pharmacies), and Region - Global Industry Insights, and Forecast till 2025

  • Published On : Apr 2018 |
  • Pages : 172 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Clostridium Difficile Diagnostics and Treatment Market – Insights

Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of C. difficile bacteria. Common symptoms of clostridium difficile infection include watery diarrhea, dehydration, fever, nausea, loss of appetite, and weight loss. Life threatening symptoms of the disease includes abdominal distension, severe abdominal pain, and profuse diarrhea. Clostridium difficile infection management includes diagnosis of the infection using various tests and medication therapies using antibiotics such as Vancomycin and Fidaxomicin.

Rising prevalence of clostridium difficile infection is expected to boost growth of the market over the forecast period

Incidence of clostridium difficile infection has been witnessing an increase in the recent past, due to clostridium difficile infection recurrence and antibiotic resistance. According to Centers for Disease Control and Prevention (CDC), 2015, around half a million people in the U.S. suffer from clostridium difficile infection in a year. Moreover, according to National Center for Biotechnology Information (NCBI), an estimated 37,900 patients were suffering from clostridium difficile infection in Canada in 2012. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016 showed significant incidence of clostridium difficile infection in China. Furthermore, according to Canadian Antimicrobial Resistance Surveillance System 2017 Report, clostridium difficile infection may be a consequence of commonly prescribed antibiotics for unrelated infections. According to Organization for Economic Co-operation and Development (OECD), 2015, antibiotic resistant bacteria are highly prevalent in G7 countries. This high presence of antibiotic resistant bacteria may lead to increasing incidence of the infection, which in turn is expected to aid in growth of the global clostridium difficile diagnostics and treatment market.

The global clostridium difficile diagnostics and treatment market was valued at US$ 1,272.2 million in 2016 and is expected to witness a robust CAGR of 8.2% over the forecast period (2017–2025).

Figure 1. Global Clostridium Difficile Diagnostics and Treatment Market Share (%) 2017 and 2025, by Region

clostridium difficile diagnostics and treatment market

Source: Coherent Market Insights Analysis (2017)

Robust pipeline of various therapies is expected to boost growth of the clostridium difficile treatment market over the forecast period

Standard antibiotic drugs such as metronidazole, Vancomycin, and Fidaxomicin have been used for the treatment of clostridium difficile infection (CDI) since the recent past.  Currently, there is no alternative therapies apart from antibiotics available for the treatment of clostridium difficile infection and only option available is surgery (in severe cases), fecal microbiota transplant, and probiotics in case of recurrent clostridium difficile infection. However, Manufacturers such as Rebiotix, Inc., Synthetic Biologics, Inc., Da Volterra, Crestovo LLC, and Immuron Ltd. have various microbiome therapeutics (new class of drugs) in pipeline for clostridium difficile infection indication. Rebiotix, Inc. has RBX7455 capsule in Phase 1 clinical trials, Synthetic Biologics Inc. has SYN-004 (ribaxamase) in Phase 2 clinical trials, and Da Volterra has DAV132 in clinical trials for antibiotic induced clostridium difficile infection. If these drugs show success in clinical trials, it could provide an alternative therapy for conventional antibiotics for treatment of the disease. Furthermore, probiotics are also gaining traction as they allow growth of natural flora through restoring natural balance of bacteria in the gut. Manufacturers such as Pfizer, Inc. and Valneva are working on developing novel vaccines for the treatment of CDI. For instance, Pfizer, Inc. has recombinant TcdA and TcdB PF-06425090 vaccine in phase 2 trial and Valneva has VLA84 in phase 1 trial.

However, low awareness about clostridium difficile infection symptoms and associated effects is expected to restrain the growth of the clostridium difficile diagnostics and treatment market over the forecast period.

Some major players operating in the clostridium difficile diagnostics and treatment market include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.

Clostridium difficile infection (CDI) is diagnosed with the help of conventional laboratory testing methods, however, rapid point-of-care diagnostic tests are also available, which can save time and costs significantly. Diagnostic assays used for detection of CDI include enzyme immunoassays (EIAs) for toxins A/B. However, these are no longer considered stand-alone primary tests due to poor sensitivity. Other tests include glutamate dehydrogenase enzyme immunoassay and molecular assay based on polymerase chain reaction. Isothermal amplification technology has also been approved by the U.S. Food & Drug Administration for diagnosis of CDI. Manufacturers such as Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic tests for clostridium difficile infection. For instance, Cepheid GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer sensitivity and timely results for clostridium difficile infection.

Market Dynamics

Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options.

Key features of the study:

  • This report provides in-depth analysis of clostridium difficile diagnostics and treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global clostridium difficile diagnostics and treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global clostridium difficile diagnostics and treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the clostridium difficile diagnostics and treatment market

Detailed Segmentation:

  • Global Clostridium Difficile Diagnostics and Treatment Market, By Product Type:
    • By Drug       
      • Metronidazole
      • Vancomycin
      • Fidaxomicin
      • Bezlotoxumab
    • By Diagnostic Test
      • Enzyme Immunoassays
      • Real-Time Polymerase Chain Reaction (RT-PCR)
      • Nucleic Amplification Tests (NAAT)
      • Others
  • Global Clostridium Difficile Diagnostics and Treatment Market, By Distribution Channel:
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Pharmacies  
  • Global Clostridium Difficile Diagnostics and Treatment Market, By Geography:
    • North America
      • By Product Type:
        • By Drug       
          • Metronidazole
          • Vancomycin
          • Fidaxomicin
          • Bezlotoxumab
        • By Diagnostic Test
          • Enzyme Immunoassays
          • Real-Time Polymerase Chain Reaction (RT-PCR)
          • Nucleic Amplification Tests (NAAT)
          • Others
      • By Distribution Channel:
        • Hospitals & Clinics
        • Diagnostic Laboratories
        • Pharmacies  
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type:
        • By Drug       
          • Metronidazole
          • Vancomycin
          • Fidaxomicin
          • Bezlotoxumab
        • By Diagnostic Test
          • Enzyme Immunoassays
          • Real-Time Polymerase Chain Reaction (RT-PCR)
          • Nucleic Amplification Tests (NAAT)
          • Others
      • By Distribution Channel:
        • Hospitals & Clinics
        • Diagnostic Laboratories
        • Pharmacies  
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • By Drug       
          • Metronidazole
          • Vancomycin
          • Fidaxomicin
          • Bezlotoxumab
        • By Diagnostic Test
          • Enzyme Immunoassays
          • Real-Time Polymerase Chain Reaction (RT-PCR)
          • Nucleic Amplification Tests (NAAT)
          • Others
      • By Distribution Channel:
        • Hospitals & Clinics
        • Diagnostic Laboratories
        • Pharmacies  
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type:
        • By Drug       
          • Metronidazole
          • Vancomycin
          • Fidaxomicin
          • Bezlotoxumab
        • By Diagnostic Test
          • Enzyme Immunoassays
          • Real-Time Polymerase Chain Reaction (RT-PCR)
          • Nucleic Amplification Tests (NAAT)
          • Others
      • By Distribution Channel:
        • Hospitals & Clinics
        • Diagnostic Laboratories
        • Pharmacies  
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • By Product Type:
        • By Drug       
          • Metronidazole
          • Vancomycin
          • Fidaxomicin
          • Bezlotoxumab
        • By Diagnostic Test
          • Enzyme Immunoassays
          • Real-Time Polymerase Chain Reaction (RT-PCR)
          • Nucleic Amplification Tests (NAAT)
          • Others
      • By Distribution Channel:
        • Hospitals & Clinics
        • Diagnostic Laboratories
        • Pharmacies  
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • By Drug       
          • Metronidazole
          • Vancomycin
          • Fidaxomicin
          • Bezlotoxumab
        • By Diagnostic Test
          • Enzyme Immunoassays
          • Real-Time Polymerase Chain Reaction (RT-PCR)
          • Nucleic Amplification Tests (NAAT)
          • Others
      • By Distribution Channel:
        • Hospitals & Clinics
        • Diagnostic Laboratories
        • Pharmacies  
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Roche AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Thermo Fisher Scientific
    • Merck & Co., Inc.
    • Pfizer, Inc.
    • Actelion Pharmaceuticals, Inc.
    • Abbott Laboratories
    • Trinity Biotech
    • Summit Therapeutics
    • Sanofi S.A.
    • Novartis AG
    • AstraZeneca Plc

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Product Launches
    • Pipeline Analysis
    • Alternative Therapies
    • Point-of-Care Vs. Conventional Diagnostic Tests
    • Drug Resistant Clostridium Difficile Infection
  4. Global Clostridium Difficile Diagnostics and Treatment Market, By Product Type, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • By Drug
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • Metronidazole
        • Vancomycin
        • Fidaxomicin
        • Bezlotoxumab
    • By Diagnostic Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
        • Enzyme Immunoassays
        • Real-Time Polymerase Chain Reaction (RT-PCR)
        • Nucleic Amplification Tests (NAAT)
        • Others
  5. Global Clostridium Difficile Diagnostics and Treatment Market, By Distribution Channel, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
    • Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Mn)
  6. Global Clostridium Difficile Diagnostics and Treatment Market, By Regions, 2015–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2016–2025
    • North America
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Thermo Fisher Scientific
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Actelion Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Trinity Biotech Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Summit Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 37 market data tables and 43 figures on "Clostridium Difficile Diagnostics and Treatment Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.